95 percent of Stage 1 Pancreatic Cancers are identified as part of the screening platform

95 percent of Stage 1 Pancreatic Cancers are identified as part of the screening platform ...

According to a pilot study inNature Communications Medicine, a novel screening platform has identified more than 95 percent of stage 1 pancreatic cancers. The approach, if validated by future research, is a potential way to detect the third-leading cause of cancer deaths in the United States in 2020.

The study of 139 stage 1 and 2 cancer patients and 184 controls is the first clinical trial of a platform technology called high-conductance di-electrophoresis, which was developed at the Moores Cancer Center at San Diego Health 12 years ago. It detects extracellular vesicles, which contain tumor proteins that are released into circulation as part of a poorly-known intercellular communication network.

The technique, which analyzed 99.5 percent of stage 1 pancreatic cancer, was identified with 74.4% of stage 1 ovarian cancer and 73.1% of pathologic stage 1A lethally aggressive serous ovarian adenocarcinomas, all with more than 99 percent specificity. This technology is intended to help early diagnosis patients.

Scott M. Lippman, MD, director of Moores Cancer Center, principal investigator of the Stand Up To CancerLustgarten Foundation Pancreatic Cancer Interception Dream Team, and co-senior author of the paper. These results are five times more accurate in detecting early-stage cancer than current liquid biopsy multi-cancer detection tests.

Liquid biopsy tests produce promising results for cancer therapy monitoring and disease relapse, according to Lippman, but they can cause real damage to otherwise healthy individuals when used for early-disease screening because of unacceptably high false-positive rates. Diagnostic tests that are not only expensive, but often dangerous.

According to the Centers for Disease Control and Prevention, early cancer detection has provided significant health benefits. These include screening methods that detect cancers of the cervix, breast, colon, and rectum when they are extremely curable. Currently, only 5 percent of pancreatic cancers are diagnosed in stage 1, but only 10 percent in time for effective surgery. In 2020, 46,774 Americans died of pancreatic cancer.

Pancreatic cancer is known to be difficult to detect early at a time when surgical resection, the only curative treatment, is generally beneficial to patients.

According to Lippman, if the study findings are verified, we can greatly reduce the mortality from this disease, which will soon become the second-leading cause of cancer mortality in the United States.

You may also like: